Bendamustine
Note: Previous Treanda formulation discontinued on 3/31/2016 by Teva to switch to Bendeka.[1]
General information
Class/mechanism: Nitrogen mustard, alkylator; bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring which forms electrophilic alkyl groups, resulting in interstrand DNA crosslinks, leading to cell death via several pathways in both quiescent and dividing cells.[2][3][4][5][6][7]
Route: IV
Extravasation: irritant (usually), vesicant (rare)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[2]
Diseases for which it is used
- B-cell lymphoma of mucosa-associated lymphoid tissue
- Chronic lymphocytic leukemia
- Cold agglutinin disease
- Cutaneous T-cell lymphoma
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- Hairy cell leukemia
- Hodgkin lymphoma
- Mantle cell lymphoma
- Marginal zone lymphoma
- Multiple myeloma
- Peripheral T-cell lymphoma
- Small cell lung cancer
- T-cell prolymphocytic leukemia
- Transformed lymphoma
- Waldenström macroglobulinemia
Patient drug information
- Bendamustine (Treanda) patient drug information (Chemocare)[8]
- Brief patient counseling information can be found in the Bendamustine (Bendeka) package insert[2]
- Brief patient counseling information can be found on page 7 of the package insert[3]
- Bendamustine (Bendeka) patient drug information (UpToDate)[9]
History of changes in FDA indication
As Treanda:
- 3/20/2008: Initial approval for the treatment of patients with chronic lymphocytic leukemia (CLL). (Based on Knauf et al. 2009)
- 10/31/2008: Approved for the treatment of patients with indolent B-cell non-Hodgkin’s lymphoma (NHL) that progressed during or within 6 months of treatment with rituximab or a rituximab containing regimen. (New disease entity; based on Kahl et al. 2010)
As Bendeka:
- 12/7/2015: Approved for chronic lymphocytic leukemia (CLL)
- 12/7/2015: Approved for indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Also known as
- Code names: CEP-18083, SDX-105, SyB L-0501
- Generic names: bendamustin hydrochloride, bendamustine hydrochloride, cytostasan hydrochloride
- Brand names: Belrapzo, Bendamax, Bendawel, Bendeka, Bendit, Innomustine, Leuben, Levact, Maxtorin, MyMust, Purplz, Ribomustin, Treakisym, Treanda, Xyotin
References
- ↑ MPR: Bendeka Injection Replacing Treanda Injection, accessed 4/2/2016
- ↑ 2.0 2.1 2.2 Bendamustine (Bendeka) package insert
- ↑ 3.0 3.1 Bendamustine (Treanda) package insert
- ↑ Bendamustine (Treanda) package insert (locally hosted backup)
- ↑ Bendamustine (Bendeka) package insert (locally hosted backup)
- ↑ Treanda manufacturer's website
- ↑ Bendeka manufacturer's website
- ↑ Bendamustine (Treanda) patient drug information (Chemocare)
- ↑ Bendamustine (Bendeka) patient drug information (UpToDate)
- Drugs
- Intravenous medications
- Vesicant
- Nitrogen mustards
- Alkylating agents
- Chronic lymphocytic leukemia medications
- Cold agglutinin disease medications
- Cutaneous T-cell lymphoma medications
- Diffuse large B-cell lymphoma medications
- Follicular lymphoma medications
- Hairy cell leukemia medications
- Hodgkin lymphoma medications
- MALT lymphoma medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Multiple myeloma medications
- Peripheral T-cell lymphoma medications
- T-cell prolymphocytic leukemia medications
- Transformed lymphoma medications
- Small cell lung cancer medications
- Waldenström macroglobulinemia medications
- FDA approved in 2008
- FDA approved in 2015
- PMDA approved drugs
- WHO Essential Cancer Medicine